According to FutureWise analysis the market for anti-rheumatics is expected to reach US$ 83.52 billion by 2031 at a CAGR of 3.10% over the forecast period of 2023-2031.
Anti-rheumatics, also known as disease-modifying antirheumatic drugs (DMARDs), refer to agents used to treat autoimmune diseases, especially rheumatoid arthritis and other forms of inflammatory arthritis. These drugs are developed to slow down the progression of the disease, reduce inflammation, and alleviate symptoms by targeting the underlying immune response that causes damage to the joints and other tissues. Rheumatoid arthritis and similar conditions are characterized by an overly active immune system that attacks healthy tissues, especially in the joints. This leads to inflammation, pain, stiffness, and joint damage. Anti-rheumatics work by modulating the immune response and suppressing the abnormal immune activity, thereby preventing or reducing the severity of joint destruction and other complications associated with these diseases.
Disease-modifying antirheumatic drugs (DMARDs) are immunosuppressive and immunomodulatory agents classified as conventional or biologic DMARDs. Commonly used conventional DMARDs include leflunomide, methotrexate, sulfasalazine, and hydroxychloroquine. Biologic DMARDs, introduced in the early 1990s, come into play when conventional DMARD therapy fails to manage disease activity or hinder radiographic or clinical progression. Some biologic agents include rituximab, infliximab, adalimumab, tofacitinib, abatacept, tocilizumab, and etanercept. These agents are highly specific and target a particular immune system pathway. Some of the drugs are monoclonal, chimeric humanized fusion antibodies, while others are receptors fused to a part of human immunoglobulin or small molecules such as Janus kinase inhibitors.
FutureWise Market Research has published a report that provides an insightful analysis anti-rheumatics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, anti-rheumatics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.